Oscar Health Reports Significant Net Loss for 2025 Driven by Higher Medical Costs and Risk Adjustment Payables
OSCR sits 20% above its 52-week low of $11.2.
Summary
Oscar Health, Inc. reported a substantial net loss of $443.15 million for the fiscal year 2025, a significant reversal from the prior year's profitability, primarily due to increased medical expenses and a surge in risk adjustment transfer payables.
Key Events · Earnings and Guidance · OSCR
-
Swing to Net Loss
The company posted a net loss of $443.15 million for the fiscal year 2025, a significant reversal from the net income of $25.43 million reported in 2024.
-
Increased Medical Loss Ratio
The Medical Loss Ratio (MLR) rose to 87.4% in 2025 from 81.7% in 2024, indicating higher medical costs relative to premiums.
-
Surge in Risk Adjustment Payables
Risk adjustment transfer payable significantly increased by over $1 billion to $2.59 billion as of December 31, 2025, primarily due to higher market morbidity and lower-than-anticipated relative risk scores.
-
Convertible Note Conversions & Dilution
$270 million in 2031 convertible notes were exchanged for approximately 32.4 million Class A common shares, plus an additional 0.7 million shares as an inducement payment, resulting in notable shareholder dilution.
Analysis · OSCR · Finance
Oscar Health's 2025 financial results mark a significant downturn, with a substantial net loss reversing the prior year's profitability. This was primarily driven by a sharp increase in medical expenses and a more than $1 billion rise in risk adjustment transfer payables, reflecting unfavorable market morbidity and the company's relative risk scores. While the company achieved notable membership growth and improved its SG&A expense ratio, these positives were insufficient to offset the escalating medical costs and risk adjustment burden. The conversion of $270 million in convertible notes into over 33 million Class A common shares also resulted in significant shareholder dilution. Furthermore, a new Congressional subpoena related to potential APTC fraud introduces additional regulatory scrutiny and risk. Although a new $475 million revolving credit facility provides a liquidity boost, the overall financial performance and regulatory challenges present a negative outlook for investors.
At the time of this filing, OSCR was trading at $13.41 on NYSE in the Finance sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $11.20 to $23.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.